NTX1088 (101164808)

  https://cordis.europa.eu/project/id/101164808

  Horizon Europe (2021-2027)

  First-in-class anti-PVR mAb NTX1088 - a novel oncology drug that unlocks the power of human immune system and revolutionizes cancer care

  EIC Accelerator Open 2023 (HORIZON-EIC-2023-ACCELERATOROPEN-01)

  immunology  ·  oncology

  2024-08-01 Start Date (YY-MM-DD)

  2028-01-31 End Date (YY-MM-DD)

  € 3,571,427

  Description

Nectin Therapeutics (NectinTx) is a venture-backed company with a top-notch team focused on innovative therapeutic options for cancer patients. To address the limitations of available therapies, the company has developed a diverse pipeline of antibodies that overcome immune inhibitory pathways deployed by the tumours. NTX1088 is a monoclonal antibody that binds human poliovirus receptor (PVR) and activates patient’s immune system to fight cancer through a triple mechanism of action never demonstrated before. A comprehensive preclinical dataset was generated to show the robust antitumor activity of NTX1088 in vitro and in vivo. Following IND approval and strong backing from key opinion leaders, Phase I clinical trial has commenced, aimed to enrol patients with solid tumours. The project will accelerate the clinical development of NTX1088 towards a novel therapy on the €80 billion immune-oncology drug market, resulting in better outcomes for patients and reduced societal and economic burden associated with cancer.

  Complicit Organisations

1 Israeli organisation participates in NTX1088.